AUTHORS
Nicholas Chien-Juei Lee, MD, Matthew Witterholt2, Jose Mercado-Matos, MD, PhD3, Willy Flegel, MD, PhD4, Ramya Ramaswami, MBBS, MPH5, Kathryn Lurain, MD, MPH6
AFFILIATIONS
1 Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States
2 National Cancer Institute, Bethesda, United States
3 National Cancer Institute, Bethesda, United States
4 Department of Laboratory Medicine, National Institutes of Health Clinical Center, Bethesda, United States
5 National Cancer Institute, Bethesda, United States
6 The Ohio State University, Columbus, United States
ABSTRACT
Introduction: Kaposi Sarcoma (KS), caused by Kaposi sarcoma herpesvirus, is a multicentric angioproliferative tumor that is most common in people with HIV (PWH). KS is a relapsing and remitting malignancy that can occur across a spectrum of CD4 T-cell counts. Standard treatment consists of chemotherapies, such as liposomal doxorubicin and paclitaxel. Infectious complications and treatment-related neutropenia are particular concerns in PWH because of underlying immune dysfunction. The Duffy-null phenotype, which is associated with 40% lower circulating absolute neutrophil counts in healthy individuals, affects 80-100% of individuals from West Africa and two-thirds of self-identified Black individuals in the United States. It has arisen because of the selective pressure from Plasmodium vivax infection. Duffy-null associated neutrophil counts have been associated with increased cancer treatment modifications, dose reductions, neutropenia-related adverse effects, and reduced clinical trial eligibility. Its clinical implications have not been evaluated in PWH receiving cancer treatment or in those with KS, all of which disproportionately impact Black individuals.
Methods: Participants with HIV-associated KS enrolled in prospective clinical trials of abemaciclib (NCT04941274) or pomalidomide-liposomal doxorubicin (pom/dox, NCT02659930). Treatment consisted of abemaciclib 200 mg twice daily on days 1-28 of a 28-day cycle or liposomal doxorubicin 20 mg/m2 on day 1 of a 28-day cycle and pomalidomide once daily on days 1-21 at escalating doses from 2-4mg. Both clinical trials required an absolute neutrophil count (ANC) > 1,000/µL at enrollment and permitted growth-factor support. In the event of recurrent neutropenia (<1,000/µL), both studies required dose reductions of the study agents. Participants had clinical red blood cell phenotyping to determine Duffy status during the course of the study. However, Duffy status did not impact clinical decisions for participants enrolled on these studies. The objective of these analyses was to evaluate the effect of Duffy status on dose reductions of treatment and safety outcomes of study participants. As these trials included patients without HIV, analysis was restricted to PWH. Categorical variables were compared using Fisher’s exact or chi-square test, continuous variables using the Wilcoxon rank-sum test, and time to dose reduction using the log-rank test.
Results: Forty-two PWH were evaluated, of whom 10 (24%) had the Duffy-null phenotype, which did not vary by study. The median age was 39 years, and 43% of patients self-identified as Black. 52% of participants had received prior chemotherapy. Baseline ANC was similar by Duffy status (Duffy-non-null 2,440/µL versus Duffy-null 2,770/µL, P = 0.64), and there were no significant differences in hemoglobin, platelets, CD4+ T-cell counts, or HIV viral load. There were no significant differences in number of cycles with neutropenia, dose reductions (Duffy-non-null 67% versus Duffy-null 33%, P = 0.48), or dose delays due to neutropenia (Duffy-non-null 65% versus Duffy-null 58%, P > 0.99). Time to dose reduction was not significantly different between Duffy-non-null and Duffy-null participants in the abemaciclib (log-rank P = 0.47) or pom/dox trials (log-rank P = 0.60). Secondary neutropenia prophylaxis with granulocyte colony stimulating factor (gCSF), due to prior episodes of neutropenia, in the overall cohort was 35% and did not differ by Duffy status. There were only 3 serious adverse events related to infections: S. dysgalactiae bacteremia and right lower extremity cellulitis in 2 Duffy-non-null and a Mpox infection in 1 Duffy-null participant.
Conclusion: KS, HIV, and Duffy-null associated neutrophil count are at higher prevalence in sub-Saharan Africa and Black/African American individuals in the United States, potentially exacerbating existing care inequities experienced by these populations. In this single center analyses of KS in PWH who were managed under uniform ANC-based criteria without regard to Duffy status, Duffy-null participants experienced no excess neutropenia, dose modifications, or infections. These findings provide no evidence that Duffy-null status requires distinct treatment thresholds and argue against introducing Duffy-based modifications that could reduce trial eligibility or intensity of therapy in a population already disproportionately affected by KS.
DISCLOSURES
Nicholas Chien-Juei Lee, MD: No relevant conflicts of interest to declare.